% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hauswald:289192,
author = {H. Hauswald$^*$ and E. Petrow$^*$ and F. Roeder$^*$ and J.
Debus and F. Zwicker$^*$ and P. Huber$^*$},
title = {{P}rimary and adjuvant intensity-modulated radiotherapy in
oropharyngeal carcinoma patients from a single institution.},
journal = {Journal of cancer research and therapeutics},
volume = {20},
number = {1},
issn = {0973-1482},
address = {Mumbai},
publisher = {Medknow Publications},
reportid = {DKFZ-2024-00626},
pages = {375 - 382},
year = {2024},
note = {#EA:E055#LA:E055#},
abstract = {To retrospectively access outcome, adverse events and
prognostic factors in oropharyngeal carcinoma (OPC) patients
treated with intensity-modulated radiotherapy
(IMRT).Ninety-eight OPC patients were treated between 2000
and 2015. Thirty-three patients received definitive and 65
adjuvant radiotherapy. Seventy-one percent had simultaneous
chemotherapy. Patients were systematically followed up (mean
114 months, range 19-197 months). Statistical analysis used
Kaplan-Meier method, Cox regression analysis, and log-rank
test. Adverse events were classified according to common
toxicity criteria version (CTCAE) 4.03.The 1-, 5-, and
10-year overall survival rates in the adjuvant vs.
definitive cohort were $90.8\%$ vs. $66.7\%,$ $67.4\%$ vs.
$33.1\%,$ and $57.7\%$ vs. $16.5\%.$ Survival in the
adjuvant cohort was significantly longer than in the
definitive cohort (P < 0.00005). Patients <65 years had a
significantly longer survival than older patients.
Locoregional tumor control rates after 1-, 5-, and 10 years
in the adjuvant vs. definitive cohort were $90.2\%$ vs.
$66.7\%,$ $82.2\%$ vs $45.4\%,$ and $72.1\%$ vs. $30.3\%.$
Locoregional tumor control in the adjuvant cohort was
significantly longer than in the definite cohort (P <
0.005). Distant metastases were diagnosed in $20.4\%$ of all
patients. Most patients had mild CTCAE grade 1 and 2 adverse
events and mild late adverse events including xerostomia,
dysphagia, and lymphedema.Intensity-modulated radiotherapy
for OPC is an important part of the treatment algorithm
alone and in particular after surgery while the additional
benefits of chemotherapy might be age dependent. Despite
advanced tumor stages, nearly half of our patients were
alive in the long term. The majority of patients had
relatively mild chronic adverse events.},
keywords = {Humans / Radiotherapy, Intensity-Modulated: adverse effects
/ Radiotherapy, Intensity-Modulated: methods / Retrospective
Studies / Oropharyngeal Neoplasms: radiotherapy /
Oropharyngeal Neoplasms: drug therapy / Oropharyngeal
Neoplasms: pathology / Radiotherapy, Adjuvant: adverse
effects / Carcinoma: etiology},
cin = {E055},
ddc = {610},
cid = {I:(DE-He78)E055-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38554349},
doi = {10.4103/jcrt.jcrt_2178_22},
url = {https://inrepo02.dkfz.de/record/289192},
}